EP0911336B1 - Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung - Google Patents

Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung Download PDF

Info

Publication number
EP0911336B1
EP0911336B1 EP97904633A EP97904633A EP0911336B1 EP 0911336 B1 EP0911336 B1 EP 0911336B1 EP 97904633 A EP97904633 A EP 97904633A EP 97904633 A EP97904633 A EP 97904633A EP 0911336 B1 EP0911336 B1 EP 0911336B1
Authority
EP
European Patent Office
Prior art keywords
group
hydrogen atom
amino
compound
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97904633A
Other languages
English (en)
French (fr)
Other versions
EP0911336A4 (de
EP0911336A1 (de
Inventor
Nobuhiko Horiuchi
Takenori Yonezawa
Katsumi Chiba
Hiroaki Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dainippon Pharmaceutical Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of EP0911336A4 publication Critical patent/EP0911336A4/xx
Publication of EP0911336A1 publication Critical patent/EP0911336A1/de
Application granted granted Critical
Publication of EP0911336B1 publication Critical patent/EP0911336B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Definitions

  • This invention relates to novel pyridonecarboxylic acid derivatives useful as antibacterial agents, and novel intermediates for the synthesis thereof.
  • Japanese Patent Laid-Open No. 239857/'94 discloses compounds of the general formula (A) wherein:
  • Japanese Patent Laid-Open No. 192262/'94 discloses compounds of the general formula (B) wherein:
  • novel pyridonecarboxylic acid derivatives of the following general formula (I) [which may hereinafter referred to as the compounds (I) of the present invention], esters thereof and salts thereof.
  • novel bicyclic amine compounds of the following general formula (II) and salts thereof which are useful as intermediates for the synthesis of pyridonecarboxylic acid derivatives of the above formula (I).
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m, n and p have the same meanings as described previously.
  • the compounds (I) of the present invention are structurally characterized by the fact that a conventionally unknown bicyclic amino group of the following general formula is joined to the 7-position of a specific pyridonecarboxylic acid or a position equivalent to the 7-position thereof.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m, n and p have the same meanings as described previously.
  • the compounds (I) of the present invention which have the above-described structural features, exhibit excellent antibacterial activity, especially against Gram-positive bacteria,. and are hence useful as antibacterial agents.
  • halogen atom comprehends, for example, fluorine, chlorine and bromine.
  • lower means that the group modified by this word contains 1 to 7 carbon atoms, unless otherwise specified.
  • lower alkyl comprehends straight-chain and branched alkyl groups having 1 to 7 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and pentyl.
  • lower alkoxy comprehends lower alkyloxy groups in which the lower alkyl portion has the above-described meaning, and examples thereof include methoxy, ethoxy, propoxy, isopropoxy and butoxy.
  • lower alkenyl comprehends straight-chain and branched alkenyl groups having 2 to 7 carbon atoms, and examples thereof include vinyl, allyl, 1-propenyl and isopropenyl.
  • lower alkynyl comprehends, for example, ethynyl and 1-propynyl.
  • lower cycloalkyl comprehends cycloalkyl groups having 3 to 7 carbon atoms, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • lower alkylthio comprehends, for example, methylthio and ethylthio.
  • the lower alkyl group, lower alkenyl group and lower cycloalkyl group which are used in the definition of R may optionally be substituted by one or more halogen atoms.
  • halogen atoms include fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2,2-difluoroethyl, 2-fluorovinyl, 1-fluorovinyl, 2,2-difluorovinyl, 2-fluorocyclopropyl and 2-chlorocyclopropyl.
  • the lower alkoxy group, lower alkyl group, lower alkylthio group, lower alkenyl group and lower alkynyl group which are used in the definition of Z may optionally be substituted by one or more halogen atoms.
  • the aforesaid groups substituted by one or more halogen atoms include, in addition to the halogen-substituted lower alkyl and lower alkenyl groups which have been described above for R, fluoromethoxy, difluoromethoxy, trifluoromethoxy, difluoromethylthio, trifluoromethylthio, fluoroethynyl and trifluoropropynyl.
  • phenyl group which may optionally be substituted by one or more halogen atoms and/or an amino group examples include 2,4-difluorophenyl, 3-amino-4,6-difluorophenyl, 4-chloro-2-fluorophenyl, 2-chloro-4-fluorophenyl and 3-amino-4-fluorophenyl.
  • the protecting group in the "amino-protecting group” or the “amino group which may be protected” there may be used any of various groups which can readily be eliminated by a common deprotection reaction such as hydrolysis or hydrogenolysis, without exerting no substantial influence on other structural parts.
  • amino-protecting groups which can readily be eliminated by hydrolysis (i.e., easily hydrolyzable amino-protecting groups) include oxycarbonyl groups such as ethoxycarbonyl, tert-butoxycarbonyl (which may be abbreviated as Boc), benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, vinyloxycarbonyl and ⁇ -(p-toluenesulfonyl)ethoxycarbonyl; acyl groups such as formyl, acetyl and trifluoroacetyl; silyl groups such as trimethylsilyl and tert-butyldimethylsilyl; and tetrahydropyranyl, o-nitrophenylsulfenyl and diphenylphosphenyl.
  • oxycarbonyl groups such as ethoxycarbonyl, tert-butoxycarbonyl (which may be abbreviated as Boc), benzyloxycarbonyl,
  • amino-protecting groups which can readily be eliminated by hydrogenolysis (i.e., easily hydrogenolyzable amino-protecting groups) include arylsulfonyl groups such as p-toluenesulfonyl; phenyl-or benzyloxy-substituted methyl groups such as benzyl, trityl and benzyloxymethyl; arylmethoxycarbonyl groups such as benzyloxycarbonyl and o-methoxybenzyloxycarbonyl; and halogenoethoxycarbonyl groups such as ⁇ , ⁇ , ⁇ -trichloroethoxycarbonyl and ⁇ -iodoethoxycarbonyl.
  • esters of the compounds (I) of the present invention there may preferably be used esters which can be converted into the compounds (I) of the present invention by eliminating the alcohol group therefrom within or outside the living body by chemical or enzymological means.
  • esters which can be converted into the corresponding free carboxylic acids by chemical means such as hydrolysis include, for example, lower alkyl esters such as methyl esters and ethyl esters.
  • the esters which can be converted into the corresponding free carboxylic acids not only by chemical means but also by enzymological means include, for example, lower alkanoyloxy-lower alkyl esters such as acetoxymethyl esters, 1-acetoxyethyl esters and pivaloyloxymethyl esters; lower alkoxycarbonyloxy-lower alkyl esters such as 1-ethoxycarbonyloxyethyl esters; aminoethyl esters such as 2-dimethylaminoethyl esters and 2-(1-piperidinyl)ethyl esters; and other esters such as 3-butyrolactonyl esters, choline esters, phthalidyl esters and (5-methyl-2-oxo-1,3-dioxo
  • physiologically acceptable salts thereof are especially preferred.
  • examples thereof include salts formed with organic acids such as trifluoroacetic acid, acetic acid, lactic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, gluconic acid and amino acids (e.g., aspartic acid and glutamic acid); salts formed with inorganic acids such as hydrochloric acid and phosphoric acid; metal salts such as sodium, potassium, zinc and silver salts; ammonium salts; and salts formed with organic bases such as trimethylamine, triethylamine and N-methylmorpholine.
  • organic acids such as trifluoroacetic acid, acetic acid, lactic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, gluconic acid and amino acids (e.g., aspartic acid and glutamic acid)
  • salts formed with inorganic acids such as hydrochloric acid and phosphoric acid
  • metal salts such as sodium
  • Salts of the bicyclic amine compounds (II) of the present invention include acid addition salts formed with inorganic acids such as hydrochloric acid and sulfuric acid; and acid addition salts formed with organic acids such as formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid and p-toluenesulfonic acid.
  • the pyridonecarboxylic acid derivatives (I) and bicyclic amine compounds (II) of the present invention may sometimes exist in the form of hydrates and solvates. Moreover, these compounds of the present invention may exist in the form of optical isomers, stereoisomers (cis- and trans-forms) or mixtures thereof. These compounds are also within the scope of the present invention.
  • Preferred examples of the compounds (I) of the present invention are the compounds of the above general formula (I) in which n is 1. Among them, the following compounds of the above general formula (I) are more preferred.
  • R is a cyclopropyl, 2-fluorocyclopropyl, 2,4-difluorophenyl or 3-amino-4,6-difluorophenyl group
  • X is a hydrogen atom, a methyl group or an amino group
  • Y is a fluorine atom
  • A is a nitrogen atom or C-Z in which Z is a hydrogen atom, a fluorine atom, a chlorine atom, a methoxy group, a difluoromethoxy group, a methyl group, a methylthio group, a vinyl group, an ethynyl group or a cyano group
  • R 1 and R 2 may be the same or different and are each a hydrogen atom or a methyl group
  • R 3 is a hydrogen atom
  • R 4 , R 5 , R 6 , R 7 , R 8 and R 9 may be the same or different
  • Preferred examples of the bicyclic amine compounds (II) of the present invention are the compounds corresponding to the substituent groups located at the 7-position of the above-described pyridonecarboxylic acid derivatives.
  • the compounds (I) of the present invention may be prepared, for example, by an amination reaction or a ring closure reaction. A typical process based on the amination reaction is explained below.
  • esters thereof and salts thereof may readily be prepared by reacting a compound of the general formula (III) wherein L is a leaving group, R, X, Y and A have the same meanings as described previously, and the carboxyl and oxo groups present in the above formula may form a boron chelate bond therebetween, an ester thereof or a salt thereof with a bicyclic amine compound of the general formula (II) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m, n and p have the same meanings as described previously; and if a boron chelate part is present in the product, hydrolyzing it.
  • Examples of the leaving group L in the general formula (III) include halogen atoms, lower alkoxy groups, lower alkylthio groups, lower alkylsulfonyl groups, lower alkylsulfinyl groups, lower alkylsulfonyloxy groups and arylsulfonyloxy groups. Among them, halogen atoms such as fluorine and chlorine are preferred.
  • the reaction of the compound (II) with the compound (III) may usually be carried out by stirring a mixture thereof in an inert solvent at a temperature of about 10 to 180°C and preferably about 20 to 130°C, for a period of time ranging from about 10 minutes to 7 days and preferably from about 30 minutes to 3 days.
  • the inert solvents which can be used for this purpose include, for example, water, methanol, ethanol, acetonitrile, chloroform, pyridine, N,N-dimethylformamide, dimethyl sulfoxide and 1-methyl-2-pyrrolidone. These solvents may be used alone or in admixture.
  • This reaction is generally carried out in the presence of an acid acceptor by using the compound (II) in an amount equivalent to or in slightly excess of that of the compound (III).
  • the compound (II) may be used in excess so as to function additionally as an acid acceptor.
  • the acid acceptor include organic bases such as 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), triethylamine. pyridine, quinoline and picoline; and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate. These acid acceptor may usually be used in an amount of about 1 to 3 moles per mole of the compound (II).
  • the amino-protecting group and/or ester may optionally be eliminated or converted. If a free acid is obtained thereby, it may be converted into a salt as required, or if a salt is obtained, it may be converted into a free acid as required.
  • the conversion of an ester into a free acid may be carried out by a hydrolysis reaction.
  • the elimination of an amino-protecting group may be carried out by subjecting the resulting compound (I) to a hydrolysis reaction or a hydrogenolysis reaction according to the type of the protecting group.
  • the hydrolysis reaction and hydrogenolysis reaction are described below.
  • the hydrolysis reaction may be carried out by bringing an ester of a compound (I) of the present invention and/or a compound (I) of the present invention having an easily hydrolyzable amino-protecting group into contact with water in a suitable solvent.
  • an acid or a base include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid; and organic acids such as acetic acid, trifluoroacetic acid, formic acid and p-toluenesulfonic acid.
  • Usable bases include metal hydroxides such as sodium hydroxide and barium hydroxide; carbonates such as sodium carbonate and potassium carbonate; and sodium acetate.
  • reaction temperature may usually range from about 0 to 150°C and preferably from about 30 to 100°C.
  • This reaction may also be carried out by heating the aforesaid compound(s) directly in the presence of an acid as described above, and then adding water thereto.
  • the elimination of an amino-protecting group by hydrogenolysis may advantageously be carried out by treating a compound (1) of the present invention having an easily hydrogenolyzable amino-protecting group with hydrogen gas in a solvent in the presence of a catalyst.
  • the catalysts which can be used in this reaction include, for example, catalysts for hydrogenation, such as platinum, palladium and Raney nickel catalyst.
  • Usable solvents include, for example, ethylene glycol, dioxane, N,N-dimethylformamide, ethanol, acetic acid and water. This reaction may be carried out at a temperature of about 60°C or below and is usually carried out at room temperature.
  • the protecting group may also be eliminated by metallic sodium treatment in liquid ammonia at a temperature of about -50 to -20°C.
  • the compounds (I) of the present invention which have been prepared by the above-described amination reaction, may be isolated and purified according to any conventional procedure. These compounds are obtained in the form of salts, free acids or hydrates, depending on the conditions of isolation and purification. However, according to the intended purposes, these forms may be changed into each other to obtain the compounds of the present invention in desired forms.
  • stereoisomers of the compounds (I) of the present invention may be separated from each other by any conventional method such as fractional crystallization or chromatography. Moreover, their optical isomers may be isolated by the application of a known optical resolution method.
  • the compounds (I) of the present invention and salts thereof which can be obtained in the above-described manner, are all novel compounds and are valuable as antibacterial agents because of their high antibacterial activities.
  • the compounds (I) of the present invention and salts thereof can be used not only as drugs for human beings and other animals, but also as agricultural chemicals, food preservatives and the like.
  • Esters of the compounds (I) of the present invention are valuable as starting materials for the synthesis of the compounds (I) of the present invention. However, if these esters themselves are readily converted into the compounds (I) of the present invention within the living body, they are useful as prodrugs. Accordingly, they may be used as antibacterial agents similarly to the compounds (I) of the present invention.
  • the compounds (II) used as starting materials in the above-described amination reaction process may be prepared, for example, by eliminating the amino-protecting group R 10 from a compound of the general formula (IV) wherein R 10 is an amino-protecting group, and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m, n and p have the same meanings as described previously, and thereby converting it into a hydrogen atom.
  • examples of the amino-protecting group R 10 include the above-described easily hydrogenolyzable amino-protecting groups and easily hydrolyzable amino-protecting groups.
  • R 1 and/or R 2 in the compound (IV) are amino-protecting groups
  • an easily hydrogenolyzable amino-protecting group such as benzyl or trityl is preferably chosen for R 10 .
  • the elimination reaction for the amino-protecting group R 10 may be carried out by subjecting the compound (IV) to a hydrogenolysis or hydrolysis reaction which has previously been explained.
  • R 1 and/or R 2 in the compound obtained as a result of this elimination reaction are amino-protecting groups, they may optionally be eliminated and converted into hydrogen atoms in the same manner. If a free base is obtained thereby, it may be converted into a salt in the usual manner as required, or if a salt is obtained, it may be converted into a free base as required.
  • stereoisomers of the compounds (II) of the present invention which are prepared in the above-described manner may be separated from each other by any conventional method such as fractional crystallization or chromatography. Moreover, their optical isomers may be isolated by the application of a known optical resolution method.
  • the terminal alcohol group of the compound 3 is sulfonylated to yield a compound 4, the alcohol-protecting groups R 11 thereof are eliminated to yield a compound 5, and this is converted into a compound 7 by ring closure.
  • the compound 7 may also be obtained by eliminating the alcohol-protecting groups R 11 of the compound 3 to yield a compound 6, and reacting this compound 6 with a sulfonylation reagent in the presence of a base. Subsequently, the hydroxyl group of the compound 7 is inverted via a compound 8 to yield a compound 9.
  • hydroxyl group of the compound 9 obtained in the above-described manner is sulfonylated and then substituted by an azide to yield a compound 10, and this is reduced to yield a compound 11.
  • a desired compound 12 falling under the category of the compounds (IV) may be obtained by protecting the amino group of the compound 11.
  • a desired compound 13 falling under the category of the compounds (IV) may be obtained by alkylating the compound 12 or by reducing the amino-protecting group R 1 ' to form a a lower alkyl group R 2 ' and then introducing an amino-protecting group R 1 '.
  • Desired compounds 16 and 17 falling under the category of the compounds (IV) may be obtained from the compound 7 in exactly the same manner as in the reaction scheme 2.
  • the alcohol-protecting group R 11 of a compound 18 is eliminated to yield a compound 19, and this is treated with a halogenation reagent to yield a compound 20.
  • the compound 20 is dehalogenated to yield a compound 21, and the hydroxyl group of the compound 21 is inverted via a compound 22 to yield a compound 23.
  • a desired compound 26 falling under the category of the compounds (IV) may be obtained from the compound 23 in exactly the same manner as in the reaction scheme 2.
  • a desired compound 29 falling under the category of the compounds (IV) may be obtained from the compound 21 in exactly the same manner as in the reaction scheme 2.
  • the compound 7 obtained in the reaction scheme 1 is oxidized to yield a compound 33, and this is reacted with a lower alkyl metal reagent to yield a compound 34.
  • the compound 34 is reduced to a compound 35.
  • a desired compound 36 falling under the category of the compounds (IV) may be obtained by the Ritter reaction.
  • the alcohol-protecting group R 11 of the compound 38 is eliminated to yield a compound 39, and this is converted into a compound 40 by ring closure.
  • the compound 40 is halogenated to yield a compound 41.
  • a desired compound 44 falling under the category of the compounds (IV) may be obtained from the compound 41 in exactly the same manner as in the reaction scheme 2.
  • Table 1 shows their minimum inhibitory concentrations (MIC; ⁇ g/ml) as measured according to the procedure described in Chemotherapy, 29 (1), 76 (1981), and Table 2 shows their effects (ED 50 ; mg/kg) on systemic infection in mice.
  • the effects (ED 50 ; mg/kg) on systemic infection in mice were determined as follows: Male Std-ddy strain mice (weighing about 20 g) were infected with each of the pathogenic bacteria shown in Table 2 by administering 5 x 10 3 viable cells intraperitoneally to each mouse. Then, a suspension of each test compound in 0.4% carboxymethylcellulose was orally administered twice, i.e., immediately after infection and 6 hours after infection. Seven days after infection, the ED 50 value was calculated from the survival rate of each mouse group by probit analysis.
  • ENX enoxacin [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; hereinafter abbreviated as ENX] that is an excellent antibacterial agent currently on the market.
  • test compounds shown in the following Tables 1 and 2 are identified by the respective numbers of the Examples which will be given later.
  • In vitro antibacterial activities MIC: ⁇ g/ml
  • the compounds (I) of the present invention exhibit an excellent in vitro antibacterial activity and in vivo effect.
  • the compounds (I) of the present invention are much more powerful than ENX (enoxacin).
  • the compounds (I) of the present invention, esters thereof, and physiologically acceptable salts thereof can suitably be used as antibacterial agents for the treatment of bacterial diseases in human beings and other animals.
  • the compounds (I) of the present invention are used as antibacterial agents in human beings, their dosage may vary according to the age and body weight of the patient, the severity of symptoms, the route of administration, and the like. However, it is recommended to administer them in a daily dose of 5 mg to 5 g which may be given once or in several divided doses. Although the route of administration may be oral, parenteral or topical, oral administration is recommended.
  • the compounds (I) of the present invention may be directly administered in their bulk form to human beings and other animals. However, they are usually combined with one or more pharmaceutically acceptable additives and administered in the form of pharmaceutical preparations (or pharmaceutical compositions).
  • pharmaceutical preparations include tablets, solutions, capsules, granules, fine subtilaes, powders, syrups, injections, suppositories, ointments, sprays, ophthalmic solutions and the like.
  • These pharmaceutical preparations may be made in the usual manner by using common additives.
  • additives for oral preparations there may be used various solid and liquid carriers or diluents which are commonly used in the field of pharmaceutics and do not react with the compounds (I) of the present invention, such as starch, mannitol, crystalline cellulose, carboxymethylcellulose calcium, water and ethanol.
  • additives for injections there may be used various additives which are commonly used in the field of injections, such as water, physiological saline, glucose solutions and transfusions.
  • the aforesaid sprays and ointments may also be used for purposes of therapy and treatment in the fields of otorhinolaryngology and ophthalmology.
  • Examples A to M relate to the preparation of bicyclic amine compounds (II) useful as intermediates
  • Examples 1 to 48 relate to the preparation of compounds (I) in accordance with the present invention
  • Example N relates to a pharmaceutical preparation.
  • the compounds (I) of the present invention are useful as antibacterial agents for human beings and other animals.
  • the bicyclic compounds (II) of the present invention are useful as direct intermediates for the synthesis of the compounds (I) of the present invention.

Claims (15)

  1. Pyridoncarbonsäurederivate der folgenden allgemeinen Formel (I), deren Ester und deren Salze
    Figure 00700001
    worin:
    R eine C1-C7-Alkylgruppe, eine C2-C7-Alkenylgruppe oder eine C3-C7-Cycloalkylgruppe (wovon alle gegebenenfalls durch ein oder mehrere Halogenatome substituiert sein können) oder eine Phenylgruppe, die gegebenenfalls durch ein oder mehrere Halogenatome und/oder eine Aminogruppe substituiert sein kann, bedeutet;
    X ein Wasserstoffatom, ein Halogenatom, eine Hydroxylgruppe, eine C1-C7-Alkylgruppe, eine C1-C7-Alkoxygruppe oder eine Aminogruppe, die geschützt sein kann, bedeutet;
    Y ein Wasserstoffatom oder ein Halogenatom bedeutet;
    A ein Stickstoffatom oder eine Gruppe der Formel C-Z bedeutet, in der Z ein Wasserstoffatom, ein Halogenatom oder eine Cyanogruppe, eine C1-C7-Alkoxygruppe, eine C1-C7-Alkylgruppe, eine C1-C7-Alkylthiogruppe, eine C2-C7-Alkenylgruppe oder eine C2-C7-Alkinylgruppe (wovon alle gegebenenfalls durch ein oder mehrere Halogenatome substituiert sein können) bedeutet, oder zusammen mit R eine Brükke bildet, die durch die Formel -O-CH2-CH(CH3)- dargestellt wird;
    R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom, eine C1-C7-Alkylgruppe oder eine Aminoschutzgruppe bedeuten;
    R3 ein Wasserstoffatom oder eine C1-C7-Alkylgruppe bedeutet;
    R4, R5, R6, R7, R8 und R9, die gleich oder unterschiedlich sein können, je ein Wasserstoffatom, ein Halogenatom oder eine C1-C7-Alkylgruppe bedeuten;
    m 0 bedeutet; und
    n und p gleich oder unterschiedlich sein können und je 0 oder 1 bedeuten.
  2. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin n 1 bedeutet.
  3. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin R eine C3-C7-Cycloalkylgruppe, die gegebenenfalls durch ein oder mehrere Halogenatome substituiert sein kann, oder eine Phenylgruppe, die durch ein oder mehrere Halogenatome und/oder eine Aminogruppe substituiert ist, bedeutet.
  4. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin X ein Wasserstoffatom, eine C1-C7-Alkylgruppe oder eine Aminogruppe bedeutet.
  5. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin Y ein Fluoratom bedeutet.
  6. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin A ein Stickstoffatom oder C-Z, worin Z ein Wasserstoffatom, ein Halogenatom, eine Cyanogruppe oder eine C1-C7-Alkoxy-, C1-C7-Alkyl-, C1-C7-Alkylthio-, C2-C7-Alkenyl- oder C2-C7-Alkinylgruppe, die gegebenenfalls durch ein oder mehrere Halogenatome substituiert sein können, ist, bedeutet.
  7. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine C1-C7-Alkylgruppe bedeuten.
  8. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin R3 ein Wasserstoffatom bedeutet.
  9. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin R4, R5, R6, R7, R8 und R9 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine C1-C7-Alkylgruppe bedeuten.
  10. Pyridoncarbonsäurederivate, deren Ester und Salze nach Anspruch 1, worin R eine Cyclopropyl-, 2-Fluorcyclopropyl-, 2,4-Difluorphenyl- oder 3-Amino-4,6-difluorphenylgruppe bedeutet; X ein Wasserstoffatom, eine Methylgruppe oder eine Aminogruppe bedeutet; Y ein Fluoratom bedeutet; A ein Stickstoffatom oder C-Z bedeutet, worin Z ein Wasserstoffatom, ein Fluoratom, ein Chloratom, eine Cyanogruppe, eine Methoxygruppe, eine Difluormethoxygruppe, eine Methylgruppe, eine Methylthiogruppe, eine Vinylgruppe oder eine Ethinylgruppe bedeutet; R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine Methylgruppe bedeuten; R3 ein Wasserstoffatom bedeutet; R4, R5, R6, R7, R8 und R9 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine Methylgruppe bedeuten; und n 1 bedeutet.
  11. Bicyclische Aminverbindung der folgenden allgemeinen Formel (II) und deren Salze
    Figure 00730001
    worin:
    R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom, eine C1-C7-Alkylgruppe oder eine Aminoschutzgruppe bedeuten;
    R3 ein Wasserstoffatom oder eine C1-C7-Alkylgruppe bedeutet;
    R4, R5, R6, R7, R8 und R9, die gleich oder unterschiedlich sein können und je ein Wasserstoffatom, ein Halogenatom oder eine C1-C7-Alkylgruppe bedeuten;
    m 0 bedeutet; und
    n und p gleich oder unterschiedlich sein können und je 0 oder 1 bedeuten.
  12. Bicyclische Aminverbindung und Säureadditionssalze davon nach Anspruch 11, worin R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom, eine C1-C7-Alkylgruppe oder eine Aminoschutzgruppe, die durch Hydrolyse eliminiert werden kann, bedeuten; R3 ein Wasserstoffatom bedeutet; R4, R5, R6, R7, R8 und R9 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine C1-C7-Alkylgruppe bedeuten; und n 1 bedeutet.
  13. Bicyclische Aminverbindung und Säureadditionssalze davon nach Anspruch 11, worin R1 und R2 gleich oder unterschiedlich sind und je ein Wasserstoffatom, eine Methylgruppe, eine tert.-Butoxycarbonylgruppe oder eine Trifluoracetylgruppe bedeuten; R3 ein Wasserstoffatom bedeutet; R4, R5, R6, R7, R8 und R9 gleich oder unterschiedlich sind und je ein Wasserstoffatom oder eine Methylgruppe bedeuten; und n 1 bedeutet.
  14. Pharmazeutisches Präparat, enthaltend als aktiven Bestandteil ein Pyridoncarbonsäurederivat nach Anspruch 1, einen Ester davon oder ein physiologisch annehmbares Salz davon.
  15. Verwendung eines Pyridoncarbonsäurederivats nach Anspruch 1, eines Esters davon oder eines physiologisch annehmbaren Salzes davon zur Herstellung eines pharmazeutischen Präparats für die Behandlung einer bakteriellen Krankheit im Menschen oder in einem anderen Tier.
EP97904633A 1996-02-27 1997-02-25 Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung Expired - Lifetime EP0911336B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP6723596 1996-02-27
JP6723596 1996-02-27
JP67235/96 1996-02-27
PCT/JP1997/000530 WO1997031919A1 (fr) 1996-02-27 1997-02-25 Derives d'acide pyridonecarboxylique et leur intermediaires de synthese

Publications (3)

Publication Number Publication Date
EP0911336A4 EP0911336A4 (de) 1999-04-28
EP0911336A1 EP0911336A1 (de) 1999-04-28
EP0911336B1 true EP0911336B1 (de) 2001-11-28

Family

ID=13339062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97904633A Expired - Lifetime EP0911336B1 (de) 1996-02-27 1997-02-25 Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung

Country Status (12)

Country Link
US (1) US6017911A (de)
EP (1) EP0911336B1 (de)
KR (1) KR19990082534A (de)
CN (1) CN1089341C (de)
AT (1) ATE209651T1 (de)
AU (1) AU704735B2 (de)
CA (1) CA2247018A1 (de)
DE (1) DE69708640T2 (de)
DK (1) DK0911336T3 (de)
ES (1) ES2165022T3 (de)
PT (1) PT911336E (de)
WO (1) WO1997031919A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023592A1 (fr) * 1996-11-28 1998-06-04 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif
DE19652219A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
WO1999010351A1 (fr) * 1997-08-22 1999-03-04 Dainippon Pharmaceutical Co., Ltd. Derives d'acide pyridonecarboxylique et intermediaires aux fins de leur preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
JPH0674261B2 (ja) * 1988-06-21 1994-09-21 塩野義製薬株式会社 キノロンカルボン酸誘導体
JPH0525162A (ja) * 1991-07-12 1993-02-02 Shionogi & Co Ltd キノロン誘導体およびその製造法
DE4232172A1 (de) * 1992-09-25 1994-03-31 Bayer Ag 7-(Aminomethyl-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)chinolon- und Naphthyridoncarbonsäure-Derivate
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives

Also Published As

Publication number Publication date
ATE209651T1 (de) 2001-12-15
CN1211986A (zh) 1999-03-24
AU704735B2 (en) 1999-04-29
US6017911A (en) 2000-01-25
DK0911336T3 (da) 2002-02-18
CA2247018A1 (en) 1997-09-04
DE69708640T2 (de) 2002-08-08
AU1735397A (en) 1997-09-16
CN1089341C (zh) 2002-08-21
WO1997031919A1 (fr) 1997-09-04
EP0911336A4 (de) 1999-04-28
DE69708640D1 (de) 2002-01-10
ES2165022T3 (es) 2002-03-01
PT911336E (pt) 2002-04-29
KR19990082534A (ko) 1999-11-25
EP0911336A1 (de) 1999-04-28

Similar Documents

Publication Publication Date Title
US4665079A (en) Antibacterial agents
EP0132845B1 (de) 1,8-Naphthyridinderivate und Verfahren zu ihrer Herstellung
US4638067A (en) Antibacterial agents
US7759340B2 (en) Antibacterial agents
CS246065B2 (en) Method of new 7-substituted cyclic aminonaphthyridine-,quinoline-and benzoxazinecarboxylic acids production
GB2188317A (en) 4-oxo-quinoline compounds
KR930005002B1 (ko) 피리돈카복실산 유도체의 제조방법
US4777175A (en) Antibacterial agents
IE63492B1 (en) A Spiro Compound
IL75021A (en) Acid 1-) 2,4-difluorophenyl (-6-fluoro-7-halo-1,4-dehydro-4-osco-1,8-) naphthyridene-3-carboxylate and its esters.
US4771054A (en) Antibacterial agents
HUT77314A (hu) Kinolon- vagy naftiridon-karbonsav-származékok és sóik, e vegyületeket tartalmazó gyógyszerkészítmény és alkalmazásuk
US5254685A (en) Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same
CZ288493B6 (en) Derivatives of 7-isoindolinylquinolone and 7-isoindolinylnaphthyridone, process of their preparation, intermediates for their preparation, their use as well as medicaments in which the derivatives are comprised
EP0387802A2 (de) 5-Substituierte 1,4-Dihydro-4-oxonaphthyridin-3-carbonsäure als antibakterielles Mittel
US5859026A (en) Quinoline carboxylic acid
EP0911336B1 (de) Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung
US5990106A (en) Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof
US5668147A (en) Quinolinecarboxylic acid derivatives and salts thereof
KR100497942B1 (ko) 광학활성을 유발하는 7-피롤리딘 치환체를 갖는 광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법
JPH03188080A (ja) ピリドンカルボン酸誘導体
KR0134940B1 (ko) 신규한 7-아미노옥시피롤리딘 퀴놀린 카르복실산 유도체 및 그의 제조방법
JPS61189281A (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩
JP2951726B2 (ja) ピリドンカルボン酸誘導体およびその合成中間体
WO1999010351A1 (fr) Derives d'acide pyridonecarboxylique et intermediaires aux fins de leur preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980820

A4 Supplementary search report drawn up and despatched

Effective date: 19990302

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991104

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011128

REF Corresponds to:

Ref document number: 209651

Country of ref document: AT

Date of ref document: 20011215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REF Corresponds to:

Ref document number: 69708640

Country of ref document: DE

Date of ref document: 20020110

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2165022

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20020125

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020400140

Country of ref document: GR

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20021218

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20021219

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20021223

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20021227

Year of fee payment: 7

Ref country code: FR

Payment date: 20021227

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030117

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20030131

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20030204

Year of fee payment: 7

Ref country code: DK

Payment date: 20030204

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030205

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20030206

Year of fee payment: 7

Ref country code: FI

Payment date: 20030206

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20030207

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030219

Year of fee payment: 7

Ref country code: BE

Payment date: 20030219

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030313

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040225

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040225

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040225

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040225

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040226

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040228

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040229

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040301

BERE Be: lapsed

Owner name: *DAINIPPON PHARMACEUTICAL CO. LTD

Effective date: 20040228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040901

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040901

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040225

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041029

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040901

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050225

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20040226